David is a co-founder of Vallon and has over 25 years of executive, operational and commercial leadership experience in the biopharmaceutical industry. He has been directly involved with the commercialization of five medications with annual sales in excess of $1 billion each, including Adderall XR® and Vyvanse®, the two most successful ADHD brands based on annual revenue.
Previously, David was the Chief Commercial Officer and interim CEO of Alcobra Ltd., a CNS specialty pharmaceutical company that completed a reverse merger with Arcturus Therapeutics in late 2017. Prior to Alcobra, he worked at Shire Plc for 10 years as Vice President of Commercial Strategy and New Business in the Neuroscience Business Unit, Global General Manager for Vyvanse® and Vice President, ADHD Marketing. Prior to Shire, he worked at Merck & Co. in marketing, sales, market research, and business development. Mr. Baker’s therapeutic expertise includes ADHD, autism, osteoporosis, migraine, and hyperlipidemia. Mr. Baker earned a bachelor’s degree in Economics and Computer Science from Duke University, and an MBA in Marketing, from Duke’s Fuqua School of Business.